SG11202002610TA - Process for the prepration of 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one derivatives - Google Patents
Process for the prepration of 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one derivativesInfo
- Publication number
- SG11202002610TA SG11202002610TA SG11202002610TA SG11202002610TA SG11202002610TA SG 11202002610T A SG11202002610T A SG 11202002610TA SG 11202002610T A SG11202002610T A SG 11202002610TA SG 11202002610T A SG11202002610T A SG 11202002610TA SG 11202002610T A SG11202002610T A SG 11202002610TA
- Authority
- SG
- Singapore
- Prior art keywords
- prepration
- dimethylimidazo
- diazaspiro
- octan
- pyridazin
- Prior art date
Links
- ASKZRYGFUPSJPN-UHFFFAOYSA-N 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one Chemical class CC1=CN2N=C(C=C(C)C2=N1)C1=CC(=O)N2C=C(C=CC2=N1)N1CCNC2(CC2)C1 ASKZRYGFUPSJPN-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
- B01J23/38—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
- B01J23/40—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals of the platinum group metals
- B01J23/44—Palladium
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
- B01J23/70—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of the iron group metals or copper
- B01J23/74—Iron group metals
- B01J23/755—Nickel
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Catalysts (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17192711 | 2017-09-22 | ||
PCT/EP2018/075282 WO2019057740A1 (fr) | 2017-09-22 | 2018-09-19 | Procédé de préparation de dérivés de 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-diméthylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202002610TA true SG11202002610TA (en) | 2020-04-29 |
Family
ID=59955477
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202002610TA SG11202002610TA (en) | 2017-09-22 | 2018-09-19 | Process for the prepration of 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one derivatives |
Country Status (14)
Country | Link |
---|---|
US (2) | US11390632B2 (fr) |
EP (1) | EP3684766A1 (fr) |
JP (2) | JP7075484B2 (fr) |
KR (2) | KR20230020580A (fr) |
CN (2) | CN111132981B (fr) |
AR (1) | AR112828A1 (fr) |
AU (1) | AU2018337597B2 (fr) |
BR (1) | BR112020005549A2 (fr) |
CA (1) | CA3075968C (fr) |
IL (1) | IL273268B2 (fr) |
MX (1) | MX2020002711A (fr) |
SG (1) | SG11202002610TA (fr) |
TW (1) | TWI812646B (fr) |
WO (1) | WO2019057740A1 (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11202002610TA (en) * | 2017-09-22 | 2020-04-29 | Hoffmann La Roche | Process for the prepration of 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one derivatives |
AU2019361273A1 (en) * | 2018-10-19 | 2021-05-06 | F. Hoffmann-La Roche Ag | New forms of pyrido[1,2-a]pyrimidin-4-one derivatives, its formulation and its process of making |
WO2022048675A1 (fr) * | 2020-09-07 | 2022-03-10 | 苏州科睿思制药有限公司 | Forme cristalline du risdiplam, son procédé de préparation et son utilisation |
WO2022162107A1 (fr) | 2021-02-01 | 2022-08-04 | Sandoz Ag | Forme cristalline de risdiplam |
JP2024510487A (ja) | 2021-03-17 | 2024-03-07 | エフ. ホフマン-ラ ロシュ アーゲー | 新規なチアジアゾロピリミドン誘導体 |
EP4308576A1 (fr) | 2021-03-17 | 2024-01-24 | F. Hoffmann-La Roche AG | Nouveaux dérivés de thiazolopyrimidinone |
BR112023018593A2 (pt) | 2021-03-18 | 2023-10-24 | Hoffmann La Roche | Processo |
WO2023170115A1 (fr) | 2022-03-10 | 2023-09-14 | F. Hoffmann-La Roche Ag | Dérivés de pyrido[1,2-a]pyrimidin-4-one |
WO2024003798A1 (fr) * | 2022-06-29 | 2024-01-04 | Biophore India Pharmaceuticals Pvt. Ltd. | Nouveau processus de préparation de 7-(4,7-diazaspiro[2,5]octane-7-yl)-2-(2,8 diméthylimidazo[1,2-b]pyridazine-6-yl)pyrido-4h-[1,2-a]pyrimidine-4-one avec de nouveaux intermédiaires |
WO2024069646A1 (fr) * | 2022-09-26 | 2024-04-04 | Natco Pharma Limited | Procédé amélioré pour la préparation de risdiplam et de ses intermédiaires |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102057351B1 (ko) * | 2011-12-30 | 2019-12-18 | 피티씨 테라퓨틱스, 인크. | 척수성 근위축증을 치료하기 위한 화합물 |
DK2812004T3 (en) | 2012-02-10 | 2018-10-15 | Ptc Therapeutics Inc | COMPOUNDS FOR TREATMENT OF SPINAL MUSCLE DROPHY |
AU2015261046C1 (en) * | 2014-05-15 | 2019-07-25 | F. Hoffmann-La Roche Ag | Compounds for treating spinal muscular atrophy |
CN105111201B (zh) * | 2014-10-16 | 2017-01-11 | 上海页岩科技有限公司 | 5-甲基-2-(吡啶-2-基氨基)-8H-吡啶并[2,3-d]嘧啶-7-酮化合物 |
MX2018005041A (es) | 2015-11-12 | 2018-08-01 | Hoffmann La Roche | Compuestos para tratar la esclerosis lateral amiotrofica. |
AU2016353961B2 (en) | 2015-11-12 | 2019-08-29 | F. Hoffmann-La Roche Ag | Compositions for treating spinal muscular atrophy |
SG11202002610TA (en) * | 2017-09-22 | 2020-04-29 | Hoffmann La Roche | Process for the prepration of 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one derivatives |
-
2018
- 2018-09-19 SG SG11202002610TA patent/SG11202002610TA/en unknown
- 2018-09-19 AU AU2018337597A patent/AU2018337597B2/en active Active
- 2018-09-19 KR KR1020237003236A patent/KR20230020580A/ko not_active Application Discontinuation
- 2018-09-19 WO PCT/EP2018/075282 patent/WO2019057740A1/fr unknown
- 2018-09-19 CN CN201880060969.4A patent/CN111132981B/zh active Active
- 2018-09-19 MX MX2020002711A patent/MX2020002711A/es unknown
- 2018-09-19 EP EP18769197.7A patent/EP3684766A1/fr active Pending
- 2018-09-19 CA CA3075968A patent/CA3075968C/fr active Active
- 2018-09-19 JP JP2020516724A patent/JP7075484B2/ja active Active
- 2018-09-19 BR BR112020005549-2A patent/BR112020005549A2/pt unknown
- 2018-09-19 KR KR1020207011439A patent/KR20200058468A/ko not_active Application Discontinuation
- 2018-09-19 CN CN202310782790.2A patent/CN116813648A/zh active Pending
- 2018-09-21 AR ARP180102704A patent/AR112828A1/es unknown
- 2018-09-21 TW TW107133307A patent/TWI812646B/zh active
-
2020
- 2020-03-12 IL IL273268A patent/IL273268B2/en unknown
- 2020-03-19 US US16/824,212 patent/US11390632B2/en active Active
-
2022
- 2022-05-13 JP JP2022079301A patent/JP7398510B2/ja active Active
- 2022-06-16 US US17/842,612 patent/US20220324881A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AR112828A1 (es) | 2019-12-18 |
WO2019057740A1 (fr) | 2019-03-28 |
US20220324881A1 (en) | 2022-10-13 |
BR112020005549A2 (pt) | 2020-10-06 |
JP7398510B2 (ja) | 2023-12-14 |
CN111132981B (zh) | 2023-10-31 |
IL273268B1 (en) | 2023-01-01 |
IL273268A (en) | 2020-04-30 |
JP7075484B2 (ja) | 2022-05-25 |
CN116813648A (zh) | 2023-09-29 |
IL273268B2 (en) | 2023-05-01 |
JP2022107003A (ja) | 2022-07-20 |
CA3075968A1 (fr) | 2019-03-28 |
TWI812646B (zh) | 2023-08-21 |
US20200216472A1 (en) | 2020-07-09 |
EP3684766A1 (fr) | 2020-07-29 |
KR20230020580A (ko) | 2023-02-10 |
MX2020002711A (es) | 2020-07-20 |
KR20200058468A (ko) | 2020-05-27 |
AU2018337597B2 (en) | 2021-03-25 |
CA3075968C (fr) | 2023-04-04 |
TW201920205A (zh) | 2019-06-01 |
JP2020534330A (ja) | 2020-11-26 |
AU2018337597A1 (en) | 2020-03-26 |
CN111132981A (zh) | 2020-05-08 |
US11390632B2 (en) | 2022-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL273268A (en) | Process for the preparation of 7-(7,4-diazespiro[2.5]octan-7-yl)-2-(8,2-dimethylimidazo[2,1-B]pyridazin-6-yl)pyrido[2,1-A] pyrimidine-4-one | |
IL261231B (en) | Mcl-1 (r)-4-methyl-3,4-dihydropyrazino[1,2-a]indol-1(2h)-one inhibitors | |
HK1255028A1 (zh) | 4-氨基-2-(1h-吡唑並[3,4-b]吡啶-3-基)-6-氧代-6,7-二氫-5h-吡咯並[2,3-d]嘧啶衍生物及其相應的(1h-吲唑-3-基)衍生物作為治療心血管疾病的cgmp調節劑 | |
HK1258157A1 (zh) | 作為jak抑制劑的吡唑並[1,5-a]吡嗪-4-基衍生物 | |
HUE059274T2 (hu) | Imidazo[4,5-d]pirrolo[2,3-b]piridin-származékok mint janus-kinázok inhibitorai | |
EP3546460A4 (fr) | Composé pyrimido[5,4-b]indolizine ou pyrimido[5,4-b]pyrrolizine, son procédé de préparation et son utilisation | |
MX2021004487A (es) | Nuevas formas de derivados de pirido[1,2-a]pirimidin-4-ona, su formulacion y su proceso de elaboracion. | |
IL270909A (en) | Imidazo[1,2-a]pyrazine modulators of the adenosine a2a receptor | |
EP3543242A4 (fr) | Composé 8,9-dihydroimidazole [1,2-a]pyrimido [5,4-e]pyrimidine -5 (6h)-cétone | |
IL266305B (en) | History of [4,2,1]triazolo[5,1-a]pyrimidine as pde2 inhibitors | |
WO2011156646A3 (fr) | 8-(sulfonylaryl)pyrido[2,3-d]pyrimidin-7(8h)-ones pour le traitement de troubles du snc | |
HK1254809A1 (zh) | 治療中有用的吡唑並[1,5-a]三嗪-4-胺衍生物 | |
EP3856743A4 (fr) | Composés imidazo [1, 2-a] pyridine et [1, 2, 4] triazolo [1, 5-a] pyridine substitués en tant qu'inhibiteurs de kinase ret | |
ZA201904236B (en) | Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as pde1 inhibitors | |
TWI800696B (zh) | 7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺衍生物 | |
IL266986B (en) | Imidazo[1,5-a]pyrazine derivatives as inhibitors of pi3k delta | |
IL262673A (en) | Pyrazolo[1,5-a]pyrimidine compound | |
ZA202000875B (en) | Imidazo[1,5-a]pyrazine derivatives as pi3kdelta inhibitors | |
IL243269A0 (en) | Crystals of (sa9,ra6)-a9,9,8,7,a6,5-hexahydro-5-methyl-3-(phenylamino)-2- ((4-(6-fluoropyridin-2-yl)phenyl)methyl ) cyclopent[5,4]imidazo[a-2,1]pyrazolo[e-3,4]pyrimidine-4(h2)-one, their salts and a process for preparing the salts. | |
EP3475286A4 (fr) | Utilisation des composés pyrrolo[2,3-d]pyridazin-4-ones et pyrazolo[3,4-d]pyridazin-4-ones substitués comme inhibiteurs de protéines kinases | |
IL281283B1 (en) | Improved method for the production of 3-[(1s)-1-imidazolo[1,2-a]pyridine-6-ylethyl]-5-(1-methylpyrazol-1-yl]triazolo[4,5-b]pyrazine and polymeric forms His | |
MX2023004924A (es) | Nuevo tratamiento de la atrofia muscular espinal (sma). | |
MX2018001350A (es) | Procesos para preparar un inhibidor de fgfr. | |
HK1257427A1 (zh) | 用於製備2-吡唑並[1,5-a]吡嗪-2-基吡啶並[1,2-a]嘧啶-4-酮的方法 | |
ZA202101933B (en) | Improved method for the manufacture of 3-[(1s)-1-imidazo[1,2-a]pyridin-6-ylethyl]-5-(1-methylpyrazol-4-yl)triazolo[4,5-b]pyrazine and polymorphic forms thereof |